Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a multicenter, 2-cohort Phase 2 study assessing both minimal residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve CLL or SLL.
Inclusion Criteria:
Exclusion Criteria:
Orange, California 92868-3201, United States
New Hyde Park, New York 11042, United States
New York, New York 10021, United States
Charlotte, North Carolina 28203, United States
Novara, 28100, Italy
Lublin, Lublin Voivodeship 20-081, Poland
Brzozów, Podkarpackie Voivodeship 36-200, Poland
Gdansk, Pomeranian Voivodeship 80-952, Poland